-2%
Mirogabalin, a γ-aminobutyric acid derivative, selectively binds to α2δ subunits of voltage-gated calcium channels (VGCCs). This reduces calcium influx at nerve endings, limiting neurotransmitter release and decreasing neuronal hyperexcitability.
- Absorption: Rapid (Tmax 0.5–1.5h)
- Protein binding: ~25%
- Distribution volume: 64–88L
- Metabolism: Minimal hepatic metabolism (UGT pathway)
- Excretion: 99% renal (mostly unchanged)
- Half-life: 2–4.9h
Migalin (Mirogabalin) Tablet
- Neuropathic Pain
- Diabetic Peripheral Neuropathic Pain (DPNP)
- Postherpetic Neuralgia (PHN)
- Peripheral Neuropathic Pain (PNP)
